Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Sofosbuvir/Daclatasvir. Show all posts
Showing posts with label Sofosbuvir/Daclatasvir. Show all posts
Tuesday, August 21, 2018

Hepatitis C - Adverse events from DAAs can persist for months after treatment

›
Of Interest March 14, 2018 Side effects associated with different hepatitis C direct-acting antiviral drugs  March 24, 2018...
Wednesday, November 29, 2017

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt

›
Alimentary Pharmacology and Therapeutics - November 29, 2017 Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment...
Tuesday, April 25, 2017

Effectiveness and Safety of Sofosbuvir-based Regimens Plus an NS5A Inhibitor for Patients With HCV Genotype 3 Infection and Cirrhosis Results of a Multicenter Real-life

›
Effectiveness and Safety of Sofosbuvir-based Regimens Plus an NS5A Inhibitor for Patients With HCV Genotype 3 Infection and Cirrhosis Result...
Tuesday, April 11, 2017

Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis

›
Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis The most recent issue of the Alimentary Pharmac...
Thursday, February 9, 2017

Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, for Hepatitis C Virus Genotype 3 in a French Early Access Programme

›
Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, for Hepatitis C Virus Genotype 3 in a French Early Access Programme Christophe Hézo...
Friday, December 2, 2016

Sofosbuvir, daclatasvir combo best treatment for HCV cryoglobulinemia vasculitis

›
Conference Coverage Sofosbuvir, daclatasvir combo best treatment for HCV cryoglobulinemia vasculitis By: Deepak Chitnis Frontline Medica...
Sunday, May 15, 2016

A Continued Role for Ribavirin in HCV Genotype 3 Infection with Advanced Liver Disease

›
A Continued Role for Ribavirin in HCV Genotype 3 Infection with Advanced Liver Disease Atif Zaman, MD, MPH reviewing L...
Wednesday, May 20, 2015

FDA Okays Hep-C Investigational Combo for Post-Transplant Patients

›
Press Release Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatit...
Saturday, April 25, 2015

BMS announces 12-week HCV regimen of daclatasvir and sofosbuvir at EASL

›
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 9...
Friday, April 24, 2015

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

›
EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Concomitant use may increase risk of slow heart rate and...